143 related articles for article (PubMed ID: 10898689)
1. Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.
Grasela DM; Stoltz RR; Barry M; Bone M; Mangold B; O'Grady P; Raymond R; Haworth SJ
Antimicrob Agents Chemother; 2000 Aug; 44(8):2149-53. PubMed ID: 10898689
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
3. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
[TBL] [Abstract][Full Text] [Related]
6. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.
Randinitis EJ; Koup JR; Rausch G; Abel R; Bron NJ; Hounslow NJ; Vassos AB; Sedman AJ
Antimicrob Agents Chemother; 2001 Sep; 45(9):2536-42. PubMed ID: 11502526
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.
Schaad HJ; Petty BG; Grasela DM; Christofalo B; Raymond R; Stewart M
Antimicrob Agents Chemother; 1997 Dec; 41(12):2793-6. PubMed ID: 9420063
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of pregabalin in subjects with various degrees of renal function.
Randinitis EJ; Posvar EL; Alvey CW; Sedman AJ; Cook JA; Bockbrader HN
J Clin Pharmacol; 2003 Mar; 43(3):277-83. PubMed ID: 12638396
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
11. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
Zomorodi K; Chen D; Lee L; Lasseter K; Marbury T
J Clin Pharmacol; 2019 Aug; 59(8):1120-1129. PubMed ID: 30865315
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.
Katsube T; Echols R; Arjona Ferreira JC; Krenz HK; Berg JK; Galloway C
J Clin Pharmacol; 2017 May; 57(5):584-591. PubMed ID: 27874971
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.
Lasseter KC; Sologuren A; La Noce A; Dilzer SC
Clin Drug Investig; 2013 Sep; 33(9):665-73. PubMed ID: 23873362
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment.
Hoover RK; Alcorn H; Lawrence L; Paulson SK; Quintas M; Luke DR; Cammarata SK
J Clin Pharmacol; 2018 Jun; 58(6):814-822. PubMed ID: 29578585
[TBL] [Abstract][Full Text] [Related]
16. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
Cass LM; Efthymiopoulos C; Marsh J; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
[TBL] [Abstract][Full Text] [Related]
17. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
18. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate.
Maia J; Almeida L; Falcão A; Soares E; Mota F; Potgieter MA; Potgieter JH; Soares-da-Silva P
Int J Clin Pharmacol Ther; 2008 Mar; 46(3):119-30. PubMed ID: 18397682
[TBL] [Abstract][Full Text] [Related]
19. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults.
Mazzu AL; Lettieri JT; Kelly E; Vargas R; Marbury T; Liu MC; Sundaresan P
Eur J Clin Pharmacol; 2000 Apr; 56(1):69-74. PubMed ID: 10853881
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
